The optimal use of cyclosporin A in rheumatoid arthritis: efficacy and outcome measures including quality of life.
The debate as to which outcome measures are appropriate in clinical trials involving RA has been in progress for some time. A recent critique (Felson DT et al. Arthritis Rheum 1990;33:140-9) addressed some of the problems that have been raised and suggested solutions. Shortcomings noted included multiple measures, lack of standardization and insensitive measures. This paper discusses those and other areas of concern in the light of the findings of consensus meetings that have taken place recently and which suggest that agreement is within reach.